Navigation Links
Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer
Date:9/10/2013

an organization that is known for its deep commitment to science and to bringing life changing medicines to patients," said Robert Landry.  "I am excited about this opportunity and look forward to working with the talented Regeneron management team."

Prior to serving as Senior Vice President and Treasurer of Pfizer, Mr. Landry held a variety of U.S. and international financial and general management positions at Wyeth and Pfizer including Senior Vice President – Finance, Pfizer's Diversified Businesses, Treasurer of Wyeth, Director of Sales and Marketing and Chief Financial Officer for Wyeth Pharmaceuticals' Australian and New Zealand affiliates, and various other assignments in both the pharmaceuticals business and the parent company.  Mr. Landry joined Wyeth after spending two years as an auditor with PricewaterhouseCoopers LLP.  He holds a B.B.A in Accounting from the University of Notre Dame.

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.Peter DworkinInvestor RelationsCorporate Communications914.847.512914.847.764manisha.narasimhan@regeneron.competer.dworkin@regeneron.com


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Regenerons Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentechs Lucentis
2. Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS
3. Regeneron Reports Second Quarter 2013 Financial and Operating Results
4. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
5. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
6. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
7. Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
8. Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
9. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... scientists increasingly are applying genomics technologies to toxicology research ... on a variety of organ systems, reports Genetic ... are especially interested in figuring out a new compound,s ... technique, according to the November 15 issue of ...
... LONDON, November 19 NeuroDiscovery Ltd (ASX:,NDL), ... development Company,and Sosei Group Corporation ("Sosei"; TSE ... today announce that NeuroSolutions,is presenting further pivotal ... is a potential therapy for neuropathic pain ...
Cached Medicine Technology:GEN Reports on the Trend Toward Predictive Toxicogenomics 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3
(Date:4/20/2014)... single type of cell in the lining of the ... cancer, according to researchers at the Stanford University School ... the first to pinpoint the normal cell type that ... the first to show that most bladder cancers and ... and explains why many human bladder cancers recur after ...
(Date:4/18/2014)... article published online in The Gerontologist ... music is associated with a decrease in anxiety about ... of control over their lives. In particular, listening to ... about death and an increase in sense of control. ... women and men, and individuals of both low- and ...
(Date:4/18/2014)... What,s one of your worst memories? How did it ... felt during a negative personal experience, such as how ... lead to emotional distress, especially when you can,t stop ... creep up, thinking about the context of the memories, ... and effective way to alleviate the negative effects of ...
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/17/2014)... PHILADELPHIA The presence of chronic inflammation in ... aggressive, prostate cancer, and this association was found ... levels, according to a study published in ... of the American Association for Cancer Research. , ... some participants of the placebo arm of the ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Religious music brings benefit to seniors' mental health 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... Exam in Their List of New Year,s Resolutions ... Improvement in Their Visual Acuity, PINELLAS PARK, Fla., Dec. 27 ... of top five New Year,s resolutions could,obtain better visual acuity and ... most common New Year,s resolutions may be to lose,weight, exercise more ...
... first nationwide clinical study showing the benefits of an ... the Dec. 27 issue of the New England Journal ... the biggest improvement in metastatic breast cancer ever reported ... time between initiation of chemotherapy for metastatic disease and ...
... Dec. 27 Computer Sciences,Corporation (NYSE: ... signed an extension to,a global information technology ... Inc., Under the five-year agreement, CSC ... support services for Sun,s business,applications portfolios -- ...
... FDA -, MENLO PARK, Calif., Dec. 27 ... drug-eluting stent (DES),systems, today announced that it has submitted ... Mark approval of its Custom NX DES,System., XTENT,s ... the,drug formulation submission from Biosensors International Group. XTENT,plans to ...
... Dec. 26 Whether it,s living and dying with,every ... the nachos and pizza,that make up the game watching ... of heartburn. Prilosec OTC, the number one selling OTC,heartburn ... opportunity to,win tickets to Super Bowl forty-two in Glendale, ...
... promising, they don,t address benefits of drug therapy , , ... wipes out abnormal heart tissue reduces the number of ... heart attacks, a new trial showed. , While those ... into abnormal rhythms, they are desirable to avoid not ...
Cached Medicine News:Health News:A New Kind of New Year's Resolution Could Bring Clarity to Americans 2Health News:A New Kind of New Year's Resolution Could Bring Clarity to Americans 3Health News:Taxol with avastin produces noteworthy results 2Health News:CSC Signs Extension to Managed Applications Services Agreement With Sun Microsystems 2Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 2Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 3Health News:Heart Procedure Reduces Need for Defibrillator Shocks 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 3
... stabilized hyaluronic acid-based dermal filler and ... the U.S. market. It is indicated ... facial wrinkles and folds (such as ... under the skins surface to replenish ...
The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results....
... Revitol Cellulite Cream is a revolutionary ... eliminating inches. Revitol Cellulite Removal Cream permits ... problem areas. With Revitol you can rid ... Just apply the Cellulite Cream to your ...
... The G5 Contour is a ... muscles, lymph nodes and the circulatory ... our famous G5 Directional-Stroking action, which ... produce effective and comfortable percussion, gyratory ...
Medicine Products: